<DOC>
	<DOC>NCT02426905</DOC>
	<brief_summary>A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.</brief_summary>
	<brief_title>Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine</brief_title>
	<detailed_description>A retrospective study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them prospectively for a further 12 months.</detailed_description>
	<mesh_term>Hepatolenticular Degeneration</mesh_term>
	<mesh_term>Penicillamine</mesh_term>
	<mesh_term>Trientine</mesh_term>
	<criteria>Patients aged 1 year to 90 years of age. Physician established diagnosis of Wilson disease based on a Ferenci score &gt; 3. Documented treatment with dPenicillamine, withdrawal of treatment with d Penicillamine, followed by treatment with trientine for at least 6 months at date of informed consent. Able/willing to provide written informed consent. For enrolment in the prospective part, enrolment in the retrospective part of the study is required. Incomplete history of medication use for trientine from initial diagnosis to latest follow up. Unavailable outcome data for hepatic and neurological course of disease at assessment time points. Patients with acute liver failure and fulminant hepatic disease with fatal outcome. Hypersensitivity to trientine and severe anaemia.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>